Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor
Status: Archived
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor
Status: Archived
Updated: 1/1/1970
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
University of Alabama, Birmingham/Department of OB/GYN
mi
from
Birmingham, AL
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
University of Alabama, Birmingham/Department of OB/GYN
mi
from
Birmingham, AL
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Solis Women's Health
mi
from
Indio, CA
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
Solis Women's Health
mi
from
Indio, CA
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Community Hospital of the Monterey Peninsula
mi
from
Monterey, CA
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
Community Hospital of the Monterey Peninsula
mi
from
Monterey, CA
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
The George Washington University Hospital
mi
from
Washington,
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
The George Washington University Hospital
mi
from
Washington,
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Boca Raton Community Hospital
mi
from
Boca Raton, FL
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
Boca Raton Community Hospital
mi
from
Boca Raton, FL
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Radiology Regional Center
mi
from
Fort Myers, FL
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
Radiology Regional Center
mi
from
Fort Myers, FL
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
OSF Saint Francis Centers for Breast Health
mi
from
Peoria, IL
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
OSF Saint Francis Centers for Breast Health
mi
from
Peoria, IL
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Kansas University Medical Center
mi
from
Kansas City, KA
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
Kansas University Medical Center
mi
from
Kansas City, KA
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Women's Hospital
mi
from
Ann Arbor, MI
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
Women's Hospital
mi
from
Ann Arbor, MI
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Henry Ford Hospital
mi
from
Detroit, MI
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
Henry Ford Hospital
mi
from
Detroit, MI
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Virginia Mason Medical Center
mi
from
Seattle, WA
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.
Status: Archived
Updated: 1/1/1970
Virginia Mason Medical Center
mi
from
Seattle, WA
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
Status: Archived
GSK Investigational Site
mi
from
Charleston, SC
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Charleston, SC
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
A Phase II Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Status: Archived
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
A Phase II Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk
Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk
Status: Archived
University of Wisconsin-Madison
mi
from
Madison, WI
Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk
Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison
mi
from
Madison, WI
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Aurora, CO
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Aurora, CO
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Roswell, GA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Roswell, GA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Ames, IA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Ames, IA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Louisville, KY
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Louisville, KY
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Grand Rapids, MI
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Grand Rapids, MI
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Cherry Hill, NJ
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Cherry Hill, NJ
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Klamath Falls, OR
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Klamath Falls, OR
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Philadelphia, PA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Philadelphia, PA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Richmond, VA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Richmond, VA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Kennewick, WA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Kennewick, WA
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
La Crosse, WI
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
La Crosse, WI
Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma
A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) for Patients Failing Radiation Therapy
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma
A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) for Patients Failing Radiation Therapy
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
A Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy
A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy
Status: Archived
Clinical Research Facility
mi
from
Detroit, MI
A Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy
A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Detroit, MI
Detection of Aggressive Breast Tumors Using Tc-99m-NC100692
Improved Sensitivity for the Detection of Aggressive Breast Tumors Using 99mTc-NC100692 and a Dual-headed Small Field of View CZT Gamma Camera.
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Detection of Aggressive Breast Tumors Using Tc-99m-NC100692
Improved Sensitivity for the Detection of Aggressive Breast Tumors Using 99mTc-NC100692 and a Dual-headed Small Field of View CZT Gamma Camera.
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver
A Phase II Feasibility Study to Assess the Use of SIR-Sphere in Patients With Breast Cancer Who Have Chemotherapy-Resistant Disease in the Liver
Status: Archived
St. Joseph's Hospital, Department of Radiation Therapy
mi
from
Tampa, FL
Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver
A Phase II Feasibility Study to Assess the Use of SIR-Sphere in Patients With Breast Cancer Who Have Chemotherapy-Resistant Disease in the Liver
Status: Archived
Updated: 1/1/1970
St. Joseph's Hospital, Department of Radiation Therapy
mi
from
Tampa, FL
Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer
Development and Implementation of a Patient-reported Outcome Questionnaire to Assess the Value of Progression-free Survival for Women With Metastatic Breast Cancer.
Status: Archived
Health Outcomes Solutions
mi
from
Winter Park, FL
Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer
Development and Implementation of a Patient-reported Outcome Questionnaire to Assess the Value of Progression-free Survival for Women With Metastatic Breast Cancer.
Status: Archived
Updated: 1/1/1970
Health Outcomes Solutions
mi
from
Winter Park, FL
Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Patients With Resectable Stage 0-II Breast Cancer
Reducing the Incidence and Severity of Arm Lymphedema With Axillary Reverse Mapping and Implementation of a Lymphedema Screening and Intervention Program
Status: Archived
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Patients With Resectable Stage 0-II Breast Cancer
Reducing the Incidence and Severity of Arm Lymphedema With Axillary Reverse Mapping and Implementation of a Lymphedema Screening and Intervention Program
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA